Clinical Nuclear Medicine

Skip Navigation LinksHome > March 2014 - Volume 39 - Issue 3 > Avastin Scintigraphy in Surveillance of Bevacizumab Treatmen...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000329
Interesting Images

Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2: A Case Report

Versleijen, Michelle W.J. MD*; Verbist, Berit M. MD; Mulder, Jef J.S. MD; de Geus-Oei, Lioe-Fee MD*; van Herpen, Carla M.L. MD§

Collapse Box


Abstract: A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment 111In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. 111In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.

© 2014 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.